SequelSEC

Rapport Therapeutics, Inc. RAPP

Pharmaceutical Preparations · CIK 0002012593 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$60.81M
Fiscal year ended 2026-06-30
Free cash flow
-$41.53M
Fiscal year ended 2026-06-30

Rapport Therapeutics, Inc. (RAPP) reported revenue of $0 and net income of -$56.62M for the fiscal year ended 2026-06-30. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Rapport Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rapport Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Revenue$0$20.00M$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$60.81M-$24.22M-$29.50M-$27.11M
Net income-$56.62M-$19.86M-$26.73M-$24.06M
Research & development$51.41M$32.72M$22.68M$19.57M
Weighted-average diluted sharesshares 47.47Mshares 47.24Mshares 35.44Mshares 35.27M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.19$-0.42$-0.75$-0.68
Selling, general & administrative$9.39M$11.50M$6.82M$7.54M
General & administrativeUnavailableUnavailable$6.82M$7.54M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

Rapport Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Cash & equivalents$63.61M$78.06M$55.07M$57.60M
Total assets$458.98M$497.60M$285.50M$302.05M
Current assets$446.86M$484.70M$270.24M$290.97M
Total liabilities$36.06M$26.08M$21.98M$16.22M
Current liabilities$28.42M$17.90M$11.88M$9.38M
Total equity incl. NCI$422.93M$471.51M$263.51M$285.84M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivable$293.00K$58.00KUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.80M$6.56M$3.18M$2.14M

Cash flow

Rapport Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Operating cash flow-$41.46M-$13.06M-$25.07M-$20.24M
Capital expenditures$78.00K$86.00K$22.00K$291.00K
Investing cash flow$25.60M$37.94M$22.60M$21.03M
Financing cash flow$1.41M$531.00K-$63.00K$5.00K
Net change in cash-$14.44M$25.41M-$2.54M$799.00K
Stock-based compensation$7.20M$6.96M$4.39M$4.04M
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$212.00K$227.00K$252.00K$244.00K

Derived

Rapport Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302025-03-31
Free cash flow-$41.53M-$13.15M-$25.09M-$20.53M
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-121.1%UnavailableUnavailable
FCF marginUnavailable-65.7%UnavailableUnavailable
SBC / revenueUnavailable34.8%UnavailableUnavailable
Current ratio15.72x27.08x22.75x31.01x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailable163.6%UnavailableUnavailable
CapEx / revenueUnavailable0.4%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RAPP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.